COVID-19 IP Waiver 'Breakthrough' At WTO Meeting
Health advocates hail the move but the EU and UK still insist a waiver is not the solution to boosting the availability of coronavirus vaccines.
You may also be interested in...
Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination
Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.